NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients

Xiaoyu Li; Fuchun Guo; Yongmei Liu; Hui-Jiao Chen; Feng Wen; Binwen Zou; Dan Li; Qin Qin; Xiaoke Liu; Yali Shen; Yongsheng Wang

doi:10.3892/ol.2015.3471

NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients

Oncol Lett. 2015 Sep;10(3):1533-1540. doi: 10.3892/ol.2015.3471. Epub 2015 Jul 8.

Authors

Xiaoyu Li¹, Fuchun Guo¹, Yongmei Liu¹, Hui-Jiao Chen², Feng Wen¹, Binwen Zou¹, Dan Li¹, Qin Qin¹, Xiaoke Liu¹, Yali Shen³, Yongsheng Wang¹

Affiliations

¹ Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
² Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.
³ Department of Abdomen Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China.

Abstract

Major histocompatibility complex (MHC) class I molecules have a crucial role in tumor immune evasion; however, the association of MHC class I molecules with outcomes in cancer patients remains controversial. Nucleotide-binding oligomerization-like receptor family caspase recruitment domain-containing 5 (NLRC5) has been reported to be a MHC class I transactivator. However, the expression and function of NLRC5 in cancer remains to be elucidated. The present study aimed to retrospectively examine NLRC5 expression in human tumor tissues and its association with clinical outcomes of non-small-cell lung cancer (NSCLC) stage III patients. The expression of MHC class I and NLRC5 in NSCLC were detected using immunohistochemistry (IHC). The association between their expression levels was assessed using the Pearson's χ² test and their association with survival was assessed using Kaplan-Meier analysis and the log-rank test. In addition, the expression of NLRC5 and MHC class I were examined in 323 cases of seven other types of tumors and their correlations were studied. The results revealed that the expression of NLRC5 was correlated with that of MHC class I in NSCLC patients (P=0.008). MHC class I-positive and nuclear NLRC5-positive NSCLC patients were found to have shorter overall survival (OS) rates (log-rank, P=0.032 and P=0.039, respectively). In addition, in the seven different tumor types, there was a significant correlation between MHC class I and NLRC5 nuclear expression (P<0.001) as well as MHC class I and NLRC5 cytoplasmic expression (P=0.003). In conclusion, NLRC5 was demonstrated to be widely expressed in eight tumor tissues and its expression was correlated with that of MHC class I. Of note, nuclear NLRC5-negative and MHC class I-negative stage III NSCLC patients had improved OS rates compared to those with positive expression. Therefore, NLRC5 and MHC class I may be negative prognostic indicators in NSCLC stage III patients.

Keywords: Nucleotide-binding oligomerization-like receptor family caspase recruitment domain-containing 5; major histocompatibility complex class I; non-small-cell lung carcinoma; prognosis indicators; tumor immune escape.